Generate Biomedicines

Historical price data

Generate Biomedicines is at the forefront of integrating machine learning, biological engineering, and medicine to create a new paradigm in drug discovery called Generative Biology™. Its proprietary platform learns from millions of proteins to generate novel therapeutics with specific functions, drastically accelerating R&D. The company has advanced a Phase 3 anti-TSLP antibody for severe asthma, built a diverse preclinical pipeline in oncology and immunology, and secured strategic collaborations, positioning it as a leader in AI-driven biotherapeutics.

The Generate Platform is a closed-loop AI system that learns from biological data to generate novel protein therapeutics, then builds, measures, and learns from them to continuously improve its designs across multiple modalities like antibodies, enzymes, and stealth proteins.

6 drugs in pipeline, 2 in Phase 3

Total raised: $420M

Generate competes with traditional biopharma companies in specific disease areas (e.g., AstraZeneca in asthma) and with a growing field of AI-driven drug discovery firms (e.g., Recursion, Exscientia). Its primary differentiation is its fully integrated, generative AI platform focused on de novo protein design and its rapid experimental validation cycle.